½ÃÀ庸°í¼­
»óǰÄÚµå
1621423

¼¼°èÀÇ ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå : Á¦Ç°º°, À¯Çüº°, ¿ëµµº° - ¿¹Ãø(2025-2030³â)

Solubility Enhancement Excipients Market by Product (Particle Size Reduction, Solid Dispersion), Type (Lipid, Polymer, Surfactant), Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀº 2023³â¿¡ 36¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 38¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.62%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 53¾ï 3,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦´Â Á¦¾à ¾÷°è¿¡¼­ ³­¼ö¿ë¼º ¾à¹°ÀÇ »ýüÀÌ¿ë·üÀ» °³¼±ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ºÎÇüÁ¦ÀÇ Çʿ伺Àº °³¹ß ÆÄÀÌÇÁ¶óÀο¡ ±×·¯ÇÑ ¾àÁ¦°¡ Á¡Á¡ ¸¹¾ÆÁö°í ÀÖ´Â °Í¿¡ ±âÀÎÇϰí ÀÖÀ¸¸ç, ¿ëÇØ¼º, ¾ÈÁ¤¼º, ÀÎü ³» Èí¼ö¸¦ ³ôÀÓÀ¸·Î½á Ä¡·áÀÇ °¡´É¼ºÀ» À̲ø¾î ³»±â ¶§¹®ÀÔ´Ï´Ù. ÀϹÝÀûÀÎ ¿ëµµ·Î´Â ƯÈ÷ Á¤Á¦³ª ĸ½¶°ú °°Àº °íÇüÁ¦Á¦ °³¹ß¿¡¼­ °æ±¸, ºñ°æ±¸, ±¹¼Ò ¹è´Þ ½Ã½ºÅÛ¿ë Á¦Á¦¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¿­Ç³Àº ÀǾàǰ»Ó¸¸ ¾Æ´Ï¶ó À¯È¿¼ººÐÀÇ È¿À²ÀûÀÎ Àü´Þ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Â ¿µ¾ç º¸Á¶½Äǰ¿¡¼­µµ ã¾Æº¼ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ÁÖ·Î ºÎÇüÁ¦ Á¦Á¶ÀÇ ±â¼úÀû Áøº¸¿Í ÇÔ²² ¸¸¼ºÁúȯ ¹ß»ý·ü »ó½Â°ú ±×¿¡ µû¸¥ ÀǾàǰ °³¹ß Ȱµ¿ Áõ°¡¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â »ý¹°ÀǾàǰ ºÐ·ù½Ã½ºÅÛ(BCS) Ŭ·¡½º II ¹× IV ÀǾàǰ ¼öÀÇ Áõ°¡, Á¦¾à±â¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ß ÅõÀÚÀÇ Áõ°¡, Á¦³×¸¯ ÀǾàǰÀ̳ª ½ÃÆÇ¾àÀÇ ¼ö¿ë È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä ºñÁî´Ï½º ±âȸ´Â ½ÅÈï ½ÃÀå, °³º°È­ ÀÇ·áÀÇ Çõ½Å, ³ª³ë Å×Å©³î·ÎÁö¿Í °ø°áÁ¤È­ ±â¼úÀÇ ÅëÇÕ¿¡ ÀÖ½À´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ, ³ôÀº Á¦Á¶ ºñ¿ë, ÀǾàǰ À¯È¿ ¼ººÐ(API)°úÀÇ ÀûÇÕ¼º ¹®Á¦·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀÌ ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù. ÂøÃ¼ Çü¼º¿¡ ÀÇÇÑ ¿ëÇØ¼º Çâ»ó, ½Å±Ô Æú¸®¸Ó Àç·á Ž»ö, ¾à¹° °¡¿ëÈ­ ±â¼úÀÇ Áøº¸¿Í °°Àº ºÐ¾ß¿¡¼­´Â ±â¼ú Çõ½ÅÀÌ °¡Àå Áß¿äÇϰí À¯¸®ÇÑ ¿¬±¸ °æ·Î¸¦ Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. ¿ëÇØ¼º Çâ»ó ÷°¡Á¦ ½ÃÀåÀÇ °æÀïÀº Ä¡¿­ÇÏÁö¸¸, Àü·«Àû Á¦ÈÞ³ª °øµ¿ °³¹ßÀÇ °¡´É¼ºÀº ÃæºÐÈ÷ ÀÖ½À´Ï´Ù. ½ÃÀå °ü°èÀÚ´Â, Á¦Á¦»óÀÇ °úÁ¦³ª ÄÄÇø®¾ð½º ¿ä°Ç¿¡ °ü·ÃÇÏ´Â ¸®½ºÅ©¸¦ °æ°¨Çϸ鼭, ÀÌ ºÐ¾ßÀÇ ¼ºÀå ±Ëµµ¸¦ Ȱ¿ëÇϱâ À§Çؼ­, »ý»ê ÇÁ·Î¼¼½º¸¦ ÃÖÀûÈ­ÇØ, Æ÷°ýÀûÀÎ ±ÔÁ¦ ÀÌÇØ¿¡ ÀÓÇÏ´Â °ÍÀ¸·Î, ÀÌ·¯ÇÑ º¹ÀâÇÑ »óȲÀ» ±Øº¹ÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 36¾ï 3,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024³â) 38¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 53¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 5.62%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû °áÁ¤ÀÇ Á¤¹ÐÈ­, ±×¸®°í »õ·Î¿î ºñÁî´Ï½º Âù½ºÀÇ È¹µæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Æ÷°ýÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖ´Â µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¦¾à»ê¾÷ ¼¼°èÀÇ ±ÞÈ®´ë
    • Æú¸®¸Ó ºÎÇüÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • °íü ºÐ»ê ±â¼úÀÇ Ã¤¿ë·üÀÌ ³ô°í, APIÀÇ »ýüÀÌ¿ë·üÀ» ³ôÀÏ Çʿ伺
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ÀÇ °íºñ¿ë
  • ½ÃÀå ±âȸ
    • ¿ëÇØ¼º Çâ»ó ±â¼úÀÇ ±â¼ú°ú °øÁ¤ ºÐ¼®ÀÇ Áøº¸
    • ¿ëÇØ¼º Çâ»óÀ» À§ÇÑ ½Å±Ô ºÎÇüÁ¦
  • ½ÃÀåÀÇ °úÁ¦
    • ºÎÇüÁ¦ÀÇ »ç¿ë¿¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë

Porter's Five Forces : ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ã±â À§ÇÑ ¸íÈ®ÇÑ ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ÆÇµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡¿¡ ´ëóÇϸç, ÀáÀçÀûÀÎ °úÁ¦¸¦ ȸÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Á¦¾à»ê¾÷ÀÇ ¼¼°èÀû ±Þ¼ÓÇÑ È®´ë
      • Æú¸®¸Ó ºÎÇüÁ¦ ¼ö¿ä Áõ°¡
      • °íü ºÐ»ê ±â¼úÀÇ Ã¤¿ë·üÀÌ ³ô°í, APIÀÇ »ýüÀÌ¿ë·üÀ» ³ôÀÏ Çʿ伺 Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ÀÇ ³ôÀº ºñ¿ë
    • ±âȸ
      • ¿ëÇØ¼º Çâ»ó ±â¼ú¿¡ °üÇÑ ±â¼ú°ú °øÁ¤ ºÐ¼®ÀÇ Áøº¸
      • ¿ëÇØ¼ºÀ» ³ôÀ̱â À§ÇÑ ½Å±Ô ÷°¡Á¦
    • °úÁ¦
      • ºÎÇüÁ¦ÀÇ »ç¿ë¿¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Á¦Ç°º° : ÀÔÀÚ Å©±âÀÇ Ãà¼Ò´Â ¾àÁ¦ÀÇ ÃæÀü È¿À²À» Çâ»ó½Ã۱â À§ÇØ ¼ÒºñÀÚÀÇ ÃëÇâ¿¡ ¸Â½À´Ï´Ù.
    • À¯Çüº° : °è¸éȰ¼ºÁ¦¸¦ ±â¹ÝÀ¸·Î ÇÑ ¾à¹° Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇϱâ À§ÇÑ ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦·Î¼­ °è¸éȰ¼ºÁ¦ÀÇ ±¤¹üÀ§ÇÑ ÀÌ¿ë
    • ¿ëµµº° : ÀǾàǰ ºÐ¾ß¿¡¼­ Á¦Ç°ÀÇ ¿ì¼ö¼ºÀ» ÃßÁøÇÏ´Â ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ÀÇ Áß¿äÇÑ ¿ªÇÒ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå : Á¦Ç°º°

  • ÀÔÀÚ Å©±âÀÇ Ãà¼Ò
  • °íü ºÐ»ê

Á¦7Àå ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå : À¯Çüº°

  • ÁöÁú
  • Æú¸®¸Ó
  • °è¸éȰ¼ºÁ¦

Á¦8Àå ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå : ¿ëµµº°

  • º´¿ø
  • ÀǾàǰ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿ëÇØ¼º Çâ»ó ºÎÇüÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Clariant, ¹Ù¸£¼¿·Î³ªÀÇ CPHI·Î APIÀÇ ¾ÈÁ¤¼º°ú ¿ëÇØ¼ºÀ» °³¼±ÇÏ´Â »õ·Î¿î ºÎÇüÁ¦ ½Ã¸®Á ¹ßÇ¥
    • Lubrizol, Çõ½ÅÀûÀÎ ¾ÆÇǼַº½º ±â¼úÀ» ¹ßÇ¥, ºñ°æ±¸ ÀǾàǰÀÇ ¿ëÇØ¼ºÀ» °³¼±ÇÏ¿© Á¦Á¶¸¦ °£¼ÒÈ­
    • Hovione ¹× Zerion Pharma°¡ ºÐ»ê ±â¼ú Ç÷§Æû ÆÇ¸Å¸¦ À§ÇÑ Àü·«Àû Á¦ÈÞ¸¦ ¹ßÇ¥
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • ABITEC Corporation
  • Air Liquide SA
  • Ashland Global Holdings Inc.
  • BASF SE
  • Cargill, Incorporated
  • Clariant International Ltd.
  • Croda International PLC
  • DuPont de Nemours Inc.
  • Evonik Industries AG
  • FMC Corporation
  • FREUND Corporation
  • Gattefosse
  • IMCD Group
  • JRS Pharma GmbH & Co. KG
  • Kerry Group PLC
  • Lubrizol Corporation
  • Merck KGaA
  • Nippon Soda Co. Ltd.
  • Pharma Excipients International AG
  • Roquette Freres SA
  • Shin-Etsu Chemical Co., Ltd.
  • Solvay SA
  • SPI Pharma Inc.
  • The DOW Chemical Company
  • Wacker Chemie AG
AJY 25.01.09

The Solubility Enhancement Excipients Market was valued at USD 3.63 billion in 2023, expected to reach USD 3.82 billion in 2024, and is projected to grow at a CAGR of 5.62%, to USD 5.33 billion by 2030.

Solubility enhancement excipients are critical in the pharmaceutical industry for improving the bioavailability of poorly water-soluble drugs. The necessity for these excipients stems from the increasing prevalence of such drugs in development pipelines, as they unlock therapeutic potential by enhancing solubility, stability, and absorption within the human body. Common applications include formulations for oral, parenteral, and topical delivery systems, particularly in the development of solid dosage forms like tablets and capsules. End-use boom is seen not only in pharmaceuticals but also in nutraceuticals, where there is an increasing demand for efficient delivery methods of active ingredients. The market is primarily driven by the rising incidence of chronic diseases and the subsequent increase in drug development activities, alongside technological advancements in excipient manufacturing. Key growth factors influencing this market include the escalating number of Biopharmaceutical Classification System (BCS) Class II and IV drugs, heightened investment in R&D by pharmaceutical companies, and the growing acceptance of generic and over-the-counter drugs. Key opportunities lie in emerging markets, personalized medicine innovations, and the integration of nanotechnology and co-crystallization techniques. However, market growth is curtailed by stringent regulation standards, high production costs, and compatibility issues with active pharmaceutical ingredients (APIs). Innovation is paramount; areas such as solubility enhancement via complexation, the exploration of novel polymeric materials, and advancements in drug solubilization technologies present lucrative pathways for research. The nature of the solubility enhancement excipients market is highly competitive but ripe with potential for strategic partnerships and co-development ventures. Market players must navigate these complexities by optimizing production processes and engaging in comprehensive regulatory understanding to capitalize on the sector's growth trajectory while mitigating risks associated with formulation challenges and compliance requirements.

KEY MARKET STATISTICS
Base Year [2023] USD 3.63 billion
Estimated Year [2024] USD 3.82 billion
Forecast Year [2030] USD 5.33 billion
CAGR (%) 5.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Solubility Enhancement Excipients Market

The Solubility Enhancement Excipients Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapid expansion of pharmaceutical industry globally
    • Rising demand for polymer excipients
    • High adoption of solid dispersion technology and need to increase the bioavailability of the API
  • Market Restraints
    • High cost of solubility enhancement excipients
  • Market Opportunities
    • Advancements in technology and process analysis for solubility enhancement techniques
    • Novel excipients for solubility enhancement
  • Market Challenges
    • Adverse effects associated with the use of excipients

Porter's Five Forces: A Strategic Tool for Navigating the Solubility Enhancement Excipients Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Solubility Enhancement Excipients Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Solubility Enhancement Excipients Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Solubility Enhancement Excipients Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Solubility Enhancement Excipients Market

A detailed market share analysis in the Solubility Enhancement Excipients Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Solubility Enhancement Excipients Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Solubility Enhancement Excipients Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Solubility Enhancement Excipients Market

A strategic analysis of the Solubility Enhancement Excipients Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Solubility Enhancement Excipients Market, highlighting leading vendors and their innovative profiles. These include ABITEC Corporation, Air Liquide S.A., Ashland Global Holdings Inc., BASF SE, Cargill, Incorporated, Clariant International Ltd., Croda International PLC, DuPont de Nemours Inc., Evonik Industries AG, FMC Corporation, FREUND Corporation, Gattefosse, IMCD Group, JRS Pharma GmbH & Co. KG, Kerry Group PLC, Lubrizol Corporation, Merck KGaA, Nippon Soda Co. Ltd., Pharma Excipients International AG, Roquette Freres SA, Shin-Etsu Chemical Co., Ltd., Solvay SA, SPI Pharma Inc., The DOW Chemical Company, and Wacker Chemie AG.

Market Segmentation & Coverage

This research report categorizes the Solubility Enhancement Excipients Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Particle Size Reduction and Solid Dispersion.
  • Based on Type, market is studied across Lipid, Polymer, and Surfactant.
  • Based on Application, market is studied across Hospitals and Pharmaceuticals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid expansion of pharmaceutical industry globally
      • 5.1.1.2. Rising demand for polymer excipients
      • 5.1.1.3. High adoption of solid dispersion technology and need to increase the bioavailability of the API
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of solubility enhancement excipients
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in technology and process analysis for solubility enhancement techniques
      • 5.1.3.2. Novel excipients for solubility enhancement
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the use of excipients
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Consumer preference for particle size reduction as it provides improved drug loading efficiency
    • 5.2.2. Type: Extensive utilization of surfactants as solubility enhancement excipients to develop surfactant-based drug delivery systems
    • 5.2.3. Application: Significant role of solubility enhancement excipients in the pharmaceutical field to drive product excellence
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Solubility Enhancement Excipients Market, by Product

  • 6.1. Introduction
  • 6.2. Particle Size Reduction
  • 6.3. Solid Dispersion

7. Solubility Enhancement Excipients Market, by Type

  • 7.1. Introduction
  • 7.2. Lipid
  • 7.3. Polymer
  • 7.4. Surfactant

8. Solubility Enhancement Excipients Market, by Application

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Pharmaceuticals

9. Americas Solubility Enhancement Excipients Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Solubility Enhancement Excipients Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Solubility Enhancement Excipients Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Clariant Launches New Range Of Excipients To Improve Stability and Solubility of APIs at CPHI Barcelona
    • 12.3.2. Lubrizol Launches Innovative Apisolex Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products
    • 12.3.3. Hovione and Zerion Pharma Announce a Strategic Partnership to Market the Dispersome Technology Platform
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABITEC Corporation
  • 2. Air Liquide S.A.
  • 3. Ashland Global Holdings Inc.
  • 4. BASF SE
  • 5. Cargill, Incorporated
  • 6. Clariant International Ltd.
  • 7. Croda International PLC
  • 8. DuPont de Nemours Inc.
  • 9. Evonik Industries AG
  • 10. FMC Corporation
  • 11. FREUND Corporation
  • 12. Gattefosse
  • 13. IMCD Group
  • 14. JRS Pharma GmbH & Co. KG
  • 15. Kerry Group PLC
  • 16. Lubrizol Corporation
  • 17. Merck KGaA
  • 18. Nippon Soda Co. Ltd.
  • 19. Pharma Excipients International AG
  • 20. Roquette Freres SA
  • 21. Shin-Etsu Chemical Co., Ltd.
  • 22. Solvay SA
  • 23. SPI Pharma Inc.
  • 24. The DOW Chemical Company
  • 25. Wacker Chemie AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦